Specific IgG subclass antibody pattern to *Aspergillus fumigatus* in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA)

M Skov, T Pressler, H E Jensen, N Høiby, C Koch

**Abstract**

**Background**—IgG and IgG subclass antibodies to *Aspergillus fumigatus* (*A. fumigatus*) were measured in a large population of patients with cystic fibrosis to elucidate a putative antibody pattern specific for allergic bronchopulmonary aspergillosis (ABPA). **Methods**—An ELISA technique using water soluble somatic hyphal (WSSH) *A. fumigatus* antigens and subclass specific monoclonal antibodies was used for cross sectional quantification of IgG and IgG subclass antibody levels in the serum of 238 patients with cystic fibrosis and 107 healthy controls.

**Results**—In patients with cystic fibrosis persistently colonised with *A. fumigatus* the subclass antibody levels were significantly increased compared with patients with cystic fibrosis never or rarely colonised (*p*<0.001). The group of patients persistently colonised with *A. fumigatus* with ABPA (+Af–ABPA) had significantly increased levels of IgG antibodies to *A. fumigatus* (Af-IgG) (median 69 ELISA units (EU) versus 31) and of subclasses Af-IgG1 (91 versus 27), Af-IgG2 (143 versus 56), and Af-IgG4 antibodies (72 versus 20), but not of IgG3 (17 versus 15), compared with the colonised patients without ABPA (+Af–ABPA). Patients with cystic fibrosis with no or only rare isolates of *A. fumigatus* without ABPA (–Af–ABPA) also had significantly increased subclass antibody levels (Af-IgG1 9 versus 3, Af-IgG2 28 versus 5, Af-IgG3 16 versus 4; *p*<0.001) compared with healthy controls. Low, although detectable, levels of antibodies were demonstrated in healthy controls. ABPA seemed to occur independently of *Pseudomonas aeruginosa* infection. Using diagnostic cut off levels for ABPA, sensitivity and specificity were calculated. The highest specificity was found for IgG3 (88%); sensitivity was between 65% and 73%. The positive predictive values (PPV) were moderate, whereas the negative predictive values (NPV) were high (96% in all subclasses except IgG1, with 94%). PPV increased to 50% if IgG3, as well as IgG2, and IgG1, were included.

**Conclusions**—In a large number of unselected patients with cystic fibrosis significantly increased levels of Af-specific antibodies belonging to total IgG and all four subclasses were found in all groups of patients compared with healthy controls. In patients persistently colonised with *A. fumigatus* these levels were significantly higher than in non-colonised patients, and the significantly highest levels (with the exception of IgG3) were found in patients with ABPA. Using a sensitive ELISA technique, measurements of IgG and IgG subclass antibodies to *A. fumigatus* might be of importance in the management of ABPA, especially as a screening test to exclude the presence of ABPA; other tests are needed to confirm the diagnosis.

(Thorax 1999;54:44–50)

**Keywords:** cystic fibrosis; allergic bronchopulmonary aspergillosis; IgG subclass antibodies

Colonisation of the lower respiratory tract with *A. fumigatus* is particularly frequent in patients with cystic fibrosis in whom an incidence of 57% and a prevalence of 40% have been reported. A sizeable minority, ranging from 1% to 11% in various reports, develop allergic bronchopulmonary aspergillosis (ABPA). The diagnosis of ABPA in patients with cystic fibrosis is more difficult than in other patients because several clinical and paraclinical findings are similar to those caused by the more frequent bacterial infections, and by atopy which is present in up to 27% of patients with cystic fibrosis. It would therefore be valuable to obtain improved diagnostic tools for the early and specific diagnosis of ABPA in patients with cystic fibrosis. Interaction of specific IgG and IgE antibodies with *A. fumigatus* antigens in the bronchial tree leads to activation of complement and mast cells resulting in mediator release and cytokine production, contributing to lung damage. We have previously demonstrated that the distribution of anti-*Pseudomonas aeruginosa* antibodies among the four IgG subclasses is related to the degree of lung damage in patients with cystic fibrosis and chronic *P. aeruginosa* infection. As an initial step we therefore undertook the present comprehensive study of specific total IgG and subclasses IgG1,4 antibodies to *A. fumigatus* in 238 unselected patients with cystic fibrosis and related the findings to the degree of colonisation with *A. fumigatus* and to the presence and absence of ABPA.
Specific IgG subclass antibody pattern to *A fumigatus* in cystic fibrosis with ABPA

**Methods**

**Patients**

The diagnosis of cystic fibrosis was based on abnormal sweat electrolytes, cystic fibrosis specific mutations, and typical clinical appearance. All patients are seen on a regular monthly basis in the Danish Cystic Fibrosis Centre. At each visit the clinical condition, pulmonary function, and sputum microbiology including plating on Sabaraud maltose agar to detect fungal growth are assessed. Serological parameters such as eosinophil count, IgE, *Af*-IgE (Radio Allergo Sorbent Test, RAST), precipitating antibodies to *A fumigatus*, and immunoglobulins G, A and M are measured at least once a year. Data have thus been recorded prospectively since 1970.

Based on data obtained over a five year period (1990–1994), all patients with cystic fibrosis were divided into three groups. Group 1: ABPA (+Af+ABPA), patients with cystic fibrosis persistently colonised with *A fumigatus* and with ABPA (median age 16.5 years (range 9–37)), n = 26; group 2: non-ABPA (+Af–ABPA), patients with cystic fibrosis persistently colonised but without ABPA (median age 19 years (range 9–44), n = 35); and group 3: non-*A fumigatus* (–Af–ABPA), patients with cystic fibrosis with no or only rare isolates of *A fumigatus* (median age 18 years (range 1–45), n = 177). The results were compared with healthy controls (group 4), a normal healthy control population aged 1–75 years (n = 107) from the serum bank at the Department of Clinical Microbiology, National University Hospital.

All serum samples from the cystic fibrosis patients were obtained within one year (1995) and with a few exceptions during the winter and stored at −20°C until use.

**Diagnosis of ABPA**

The “golden standard” diagnostic criteria for ABPA are, according to Nelson: (1) radiological pulmonary infiltrates, (2) wheezing, (3) positive Aspergillus cultures, (4) positive immediate type reaction by epidermal skin test with *A fumigatus*, (5) increased serum levels of total IgE, (6) increased serum levels of *A fumigatus* specific IgE and, (7) increased serum levels of *A fumigatus* precipitating antibodies. Pulmonary infiltrates and wheezing are, however, extremely common in cystic fibrosis, and atopy, including presence of *A fumigatus* specific IgE, is more frequent than in the background population. The specificity of these criteria is therefore low in patients with cystic fibrosis. In the present study we therefore defined ABPA as the persistent presence of *A fumigatus* in lower tract secretions, combined with persistent abnormally raised titres of *A fumigatus* specific IgE and precipitating antibodies over the five year observation period. *A fumigatus* specific precipitating antibodies, expressed as titre, were measured at the Department of Clinical Microbiology, University Hospital, Aarhus (normal value <2) and specific *A fumigatus* IgE antibodies were measured at the Laboratory of Medical Allergology, National University Hospital, Copenhagen (normal value, RAST class 0).

Diagnostic cut off levels for the diagnosis of ABPA were determined for IgG and IgG subclass antibodies.

**Preparation of *A fumigatus* antigen**

Following the disintegration of mycelial mats of *A fumigatus* strain ATCC 42202 in an X-press operated at a maximal force of 200 MPa at −30°C, preparation of water soluble somatic hyphal (WSSH) antigens were prepared as described previously.7 The protein concentration was measured using a refractometer (TS meter, AO Scientific Instruments, Alabama, USA). The antigen preparation was stored (from 1992 until use (1996)) at −80°C.

**ELISA**

ELISA assays similar to those used previously in our laboratory were established.8 Irradiated 96-well polystyrene microtitre plates (Nunc-Immuno-Plate, Maxisorb, Nunc, Denmark) and reagent volumes of 100 µl were used. All incubation steps were carried out at 22°C. Between each step the plates were washed in phosphate buffer saline (PBS) with 0.1% Tween 20 (Bie & Berntsen, Denmark), pH 7.2. Antigen was diluted 1:10 000 for IgG and 1:1000 for IgG subclasses in PBS and incubated for one hour (0.5 µg of protein per well for IgG and 5.1 µg per well for IgG subclasses) at room temperature (22°C). The samples for IgG measurements reacted overnight (18 hours) at 5°C after coating. Additional binding sites in the wells were blocked with the PBS, 0.1% Tween 20. Serum samples were diluted 1:4000 for IgG measurements. IgG subclass samples were incubated with antigen for an hour and blocked with PBS and serum in a dilution of 1:400 before they were allowed to react overnight at 22°C. Peroxidase-conjugated rabbit anti-human IgG specific for gamma chains (Dako, Denmark) and mouse monoclonal anti-human IgG4 conjugated to horse radish peroxidase (HRP) (Central Laboratory of the Red Cross, The Netherlands) were added and incubated for one hour. The specific antibodies were diluted 1:10 000 for IgG, 1:60 000 for IgG2, 1:3000 for IgG3, 1:2000 for IgG4, and 1:20 000 for IgG4. To each well 1,2-phenylenediame solution (0.1 M citric acid-phosphate buffer, pH 5.0; Dako, Denmark) containing 5 µl H2O2 per plate was added. After incubation for one hour the reaction was stopped by adding H2SO4 (1 M). The optical density (OD) was measured using an ELISA plate reader (492 nm, Bio-rad, Japan). All measurements were performed in duplicate. The antigen concentration and serum and antibody dilutions used in the present assays were chosen from serial dilutions carried out in pilot studies. A standard pool of serum from six cystic fibrosis patients colonised with *A fumigatus* was used for calibration for each plate. A logarithmic curve was drawn from the results of the standard serum in each plate. The values were determined in relation to the curve and expressed in ELISA units (EU).8
ASSESSMENT OF ANTIGENIC SPECIFICITY OF THE ASSAY

P aeruginosa and Staphylococcus aureus are common causes of pulmonary infection in patients with cystic fibrosis and most have increased specific antibody titres against these organisms. The influence of antibodies to these bacteria on specific Aspergillus antibodies was assessed. Another fungus, Candida albicans, which is known to be present in the lungs of patients with cystic fibrosis, was also absorbed. Standard serum samples diluted 1:10 000 for IgG and 1:1000 for IgG subclasses were absorbed with increasing amounts of sonicated preparations of P aeruginosa, S aureus (protein A-deficient strain to avoid reaction with the Fc part of IgG) and C albicans. The absorption was compared with similar absorption performed with A fumigatus antigen.

REPRODUCIBILITY OF THE ASSAY

Twelve serum samples from cystic fibrosis patients colonised with A fumigatus (samples covering the spectrum from low to high levels) were tested in duplicate in two different plates on two different days. The intraplate, plate-to-plate, and day-to-day variations were determined using the formula: standard deviation (SD) = (∑d^2/2n), where ∑d^2 = the sum of the squared differences of double determinations of the same sample, and n = the number of observations.

Figure 1  Antigenic specificity of the assay expressed as increasing % inhibition (decreasing antibody activity) after absorption of the standard serum with increasing amounts of antigen preparations of A fumigatus, P aeruginosa, S aureus, and C albicans.

Figure 2  A fumigatus-IgG and IgG subclass antibody levels in 107 healthy controls. A = IgG, B = IgG1, C = IgG2, D = IgG3, E = IgG4. Values are given in ELISA units (EU). The box plots show the 10th, 25th, 50th, 75th, and 90th percentiles. Values above and below are shown separately.
ANALYSIS OF DATA

Sensitivity (SE), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) were calculated according to the guidelines from the Workshop on Experimental Methodology. An optimal diagnostic cut off level for ABPA was determined, giving maximum improvements for diagnostic accuracy, which means improving SE without losing SP, or increasing SP without decreasing SE.

To compare all four groups the non-parametric equivalent of an analysis of variance (the Kruskal Wallis test) was performed. The Mann-Whitney U test for non-parametric unpaired data was used within the groups whenever the Kruskal Wallis test was significant. p values of <0.05 were considered significant. The values given are medians (range). For independence the $\chi^2$ test was used.

Results

SPECIFICITY AND REPOR DUCIBILITY OF THE ASSAYS

Absorption with increasing amounts of A fumigatus antigen resulted in decreased antibody activity (increased inhibition) in IgG as well as IgG subclasses. Absorption with either P aeruginosa, S aureus, or C albicans antigen resulted in only a minor reduction in the antibody activity (fig 1).

The intraplate variation was 15%, 10%, 17%, 11%, and 17%, respectively, for IgG, IgG1, IgG2, IgG3, and IgG4. The interplate variation was 17%, 9%, 13%, 16%, and 14% and the day-to-day variation was 8%, 27%, 15%, 10%, and 17%, respectively.

IgG AND IgG SUBCLASS ANTIBODIES TO A FUMIGATUS IN SERUM FROM HEALTHY CONTROLS

Low levels of IgG and IgG subclass antibodies to A fumigatus were seen in healthy controls (fig 2).

IgG AND IgG SUBCLASS ANTIBODIES TO A FUMIGATUS IN SERUM FROM PATIENTS WITH CYSTIC FIBROSIS AND HEALTHY CONTROLS

Figure 3 shows the levels of IgG and IgG subclasses specific antibodies to A fumigatus in serum samples from patients with cystic fibrosis and controls. In cystic fibrosis patients
Chronic *P aeruginosa* infection in the three groups of patients with cystic fibrosis: ABPA (+A*F*+ABPA), non-ABPA (+A*F*–ABPA) and non-*A fumigatus* (–A*F*–ABPA).

Fig 4 Distribution of chronic, intermittent, or no *P aeruginosa* infection in the three groups of patients with cystic fibrosis: ABPA (+A*F*+ABPA), non-ABPA (+A*F*–ABPA) and non-*A fumigatus* (–A*F*–ABPA).

Rarely colonised with *A fumigatus* (group 3) significantly higher IgG (p<0.001) as well as IgG₄, antibody levels (p<0.001) were observed compared with controls. The most marked increases were observed in patients persistently colonised with *A fumigatus* (groups 1 and 2). Significantly higher IgG and IgG subclass antibody levels were observed for both groups compared with patients rarely colonised (group 3; p<0.001). Patients persistently colonised with *A fumigatus* with ABPA (group 1) had significantly higher IgG and IgG₃, IgG₄, and IgG₅ (p<0.001) antibody levels, whereas the IgG₂ antibody level was not significantly increased (p = 0.8) compared with persistently colonised patients without ABPA (group 2; fig 3).

Sensitivity, specificity, PPV and NPV

Distinction between cystic fibrosis patients with ABPA and those without ABPA (with or without *A fumigatus* colonisation) was made using diagnostic cut off levels in each IgG subclass antibody. The sensitivity (% of patients with ABPA with a positive test), specificity (% of patients without ABPA with a negative test), positive predictive value (PPV = % of patients with a positive test with ABPA), and negative predictive value (NPV = % of patients with a negative test without ABPA) were calculated. The diagnostic cut off levels for ABPA were ≥40 EU for IgG₁, ≥40 EU for IgG₂, ≥60 EU for IgG₃, ≥15 EU for IgG₄, and ≥35 EU for IgG₅. Sensitivity was calculated to be 69%, 73%, 73%, and 73% respectively, for IgG₁, IgG₂, IgG₃, IgG₄, and IgG₅. Specificity was 82%, 85%, 77%, 67%, and 88%, PPV was 32%, 37%, 29%, 10%, and 43%, and NPV was 96%, 96%, 94%, 96%, and 96% respectively. The specificity increased to 93% and the PPV to 50% if IgG₁, IgG₂, and IgG₅ were combined.

**Correlation between *P aeruginosa* status and *A fumigatus* status**

The three groups of cystic fibrosis patients were correlated according to their *P aeruginosa* status. A possible predisplosion to colonisation with *A fumigatus* in patients chronically colonised with *P aeruginosa* was examined. The *P aeruginosa* status was either chronic, intermittent, or none at the time of the study. Chronic *P aeruginosa* means positive *P aeruginosa* culture in six succeeding months or shorter if there is a significant increase in specific precipitating antibodies to *P aeruginosa* (≥2); intermittent *P aeruginosa* means positive *P aeruginosa* culture at least once with normal precipitating antibodies to *P aeruginosa* (0–1). A similar distribution of chronic colonisation with *P aeruginosa* was seen in the three groups (group 1 versus 2, p = 0.28; group 2 versus 3, p = 0.26); 60% in the ABPA group, 65% in the non-ABPA group, and 51% in the non-*Aspergillus* group. Intermitent colonisation with *P aeruginosa* was seen in 23%, 23%, and 21% and no colonisation in 19%, 14%, and 28% in the ABPA, non-ABPA and non-*Aspergillus* groups, respectively (fig 4).

Discussion

This study demonstrates a specific Af-IgG subclass pattern in cystic fibrosis patients with ABPA (+A*F*+ABPA), with significantly increased levels of Af-IgG₁, Af-IgG₂, and Af-IgG₅, but not Af-IgG₃, compared with non-ABPA (+A*F*–ABPA) cystic fibrosis patients. Both of these patient groups had significantly increased levels of all Af-IgG subclasses compared with the non-*Aspergillus* colonised patients with cystic fibrosis (–A*F*–ABPA). Furthermore, in the latter group significantly higher levels in all four IgG subclasses were found compared with healthy controls. Thus, generally higher levels of IgG and IgG subclass antibodies to *A fumigatus* were seen in all patients with cystic fibrosis compared with healthy controls of comparable age. Low but detectable levels of all four subclasses of antibodies were found in all the healthy controls.

The highest specificity for the diagnosis of ABPA was reported in subclass IgG₁ (88%), which increased to 92% if IgG₁ and IgG₂ were also included. The PPV was moderate with IgG and the IgG subclasses while the NPV was high (96%, except 94% in IgG₅). With Af-IgG, the specificity of total IgG and 96% NPV, measurements of total IgG alone may be as useful as measurement of the subclasses. Determination of IgG and IgG subclass antibody levels may be particularly valuable as a screening test to exclude the presence of ABPA. Other tests still have to be used to confirm the diagnosis of ABPA.

The assays presently used have high antigen specificity with regard to IgG and the IgG subclasses. With an analytical variation similar to other assays used for the determination of *A fumigatus* IgG antibodies⁴ ⁵ or *P aeruginosa* subclass antibodies,⁶ ⁷ the reproducibility was acceptable. The ELISA assays were calibrated with pooled high titre serum samples and therefore the precision of the measurement may decrease slightly with very low levels of antibodies. Most of the serum samples were obtained in the winter time to avoid a possible seasonal variation in exposure to *A fumigatus*.

In various studies patients with cystic fibrosis have been divided into groups according to increasing positivity to different *A fumigatus* specific tests.¹⁶ ¹⁸ All these studies have shown the same gradual increase of all the IgG subclasses with increasingly positive *A fumigatus* specific tests, much like the grouping in this
Specific IgG subclass antibody pattern to A fumigatus in cystic fibrosis with ABPA

An association between P aeruginosa colonization and the development of ABPA was reported by Nikolazik et al.1 This is in contrast to a previous report by Nelson et al., as the present findings, showing that ABPA occurs independently of P aeruginosa infection.

In conclusion, measurements of IgG and IgG subclass antibodies to A fumigatus, using a multivalent antigen extract and ELISA techniques, may be valuable in the diagnosis of ABPA, especially as a screening test to exclude the diagnosis. Confirmation of the diagnosis still requires other tests. We have shown a specific pattern of significantly increased Af-IgGζ, Af-IgGζ, and Af-IgGζ, but not Af-IgGζ, antibody levels in patients with ABPA. Measurement of the IgGζ antibody was most specific in establishing the diagnosis of ABPA. The NIV was high in IgGζ as well as in all subclasses.

Further longitudinal studies of IgG subclass antibodies to follow fluctuations in the levels due to changes in disease activity are needed for appropriate medication. Early diagnosis and treatment of ABPA may be of importance in the prevention of serious and potentially irreversible lung damage.

This study was supported by The Ville Heise Foundation and The Danish Research Councils.


Specific IgG subclass antibody pattern to *Aspergillus fumigatus* in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA)

M Skov, T Pressler, H E Jensen, N Høiby and C Koch

*Thorax* 1999 54: 44-50
doi: 10.1136/thx.54.1.44

Updated information and services can be found at: [http://thorax.bmj.com/content/54/1/44](http://thorax.bmj.com/content/54/1/44)

These include:

**References**
This article cites 20 articles, 2 of which you can access for free at: [http://thorax.bmj.com/content/54/1/44#BIBL](http://thorax.bmj.com/content/54/1/44#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Cystic fibrosis (525)
- Fungal lung diseases (51)
- TB and other respiratory infections (1273)
- Screening (epidemiology) (366)
- Screening (public health) (366)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)